The Effect of Phototherapy on Fecal Calprotectin Levels

Abstract

Objective Fetal calprotectin levels increase in the early stages of necrotizing enterocolitis. Although the effects of several factors on fetal calprotectin have been studied, the effect of phototherapy is not known. In this study, we analyzed the effect of phototherapy on fetal calprotectin levels.

Methods Ninety breast-fed newborns (46 male, 44 female) who were hospitalized for indirect hyperbilirubinemia and treated with phototherapy were included to the study. Forty-two of them were term and 44 of them were preterm. Newborns treated with phototherapy (n = 53) constituted the phototherapy group (29 preterm, 24 term) and 37 newborns who did not receive phototherapy (19 preterm, 18 term) constituted the control group. Fecal samples were collected 24 hours after phototherapy had been started. Fecal samples (100 mg) were weighed with sensitive scales and preserved at −80°C after buffering with a special solution. All samples were studied at the same time with a fecal calprotectin kit by using enzyme-linked immunosorbent assay.

Results There were no statistically significant difference between fecal calprotectin levels of term and preterm babies who received phototherapy and babies who did not receive phototherapy.

Conclusion There was no effect of 24-hour phototherapy on fecal calprotectin levels in preterm and term newborns.

Keywords

calprotectin - phototherapy - newborns

• References

• 1 Berntzen HB, Fagerhol MK. L1, a major granulocyte protein; isolation of high quantities of its subunits. Scand J Clin Lab Invest 1990; 50: 769-774
• 2 Poullis A, Foster R, Mendall MA, Fagerhol MK. Emerging role of calprotectin in gastroenterology. J Gastroenterol Hepatol 2003; 18: 756-762
• 3 Steinbakk M, Naess-Andresen CF, Lingaas E, Dale I, Brandtzaeg P, Fagerhol MK. Antimicrobial actions of calcium binding leucocyte L1 protein, calprotectin. Lancet 1990; 336: 763-765
• 4 Tøn H, Brandsnes S , et al. Improved assay for fecal calprotectin. Clin Chim Acta 2000; 292: 41-54
• 5 Røseth AG, Schmidt PN, Fagerhol MK. Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. Scand J Gastroenterol 1999; 34: 50-54
• 6 Bjarnason I, MacPherson A, Hollander D. Intestinal permeability: an overview. Gastroenterology 1995; 108: 1566-1581
• 7 Nissen AC, van Gils CE, Menheere PP, Van den Neucker AM, van der Hoeven MA, Forget PP. Fecal calprotectin in healthy term and preterm infants. J Pediatr Gastroenterol Nutr 2004; 38: 107-108
• 8 Rugtveit J, Fagerhol MK. Age-dependent variations in fecal calprotectin concentrations in children. J Pediatr Gastroenterol Nutr 2002; 34: 323-324 ; author reply 324–325
• 9 Olafsdottir E, Aksnes L, Fluge G, Berstad A. Faecal calprotectin levels in infants with infantile colic, healthy infants, children with inflammatory bowel disease, children with recurrent abdominal pain and healthy children. Acta Paediatr 2002; 91: 45-50
• 10 Campeotto F, Butel MJ, Kalach N , et al. High faecal calprotectin concentrations in newborn infants. Arch Dis Child Fetal Neonatal Ed 2004; 89: F353-F355
• 11 Josefsson S, Bunn SK, Domellöf M. Fecal calprotectin in very low birth weight infants. J Pediatr Gastroenterol Nutr 2007; 44: 407-413
• 12 Campeotto F, Kalach N, Lapillonne A, Butel MJ, Dupont C, Kapel N. Time course of faecal calprotectin in preterm newborns during the first month of life. Acta Paediatr 2007; 96: 1531-1533
• 13 Yang Q, Smith PB, Goldberg RN, Cotten CM. Dynamic change of fecal calprotectin in very low birth weight infants during the first month of life. Neonatology 2008; 94: 267-271
• 14 Laforgia N, Baldassarre ME, Pontrelli G , et al. Calprotectin levels in meconium. Acta Paediatr 2003; 92: 463-466
• 15 Fagerberg UL, Lööf L, Myrdal U, Hansson LO, Finkel Y. Colorectal inflammation is well predicted by fecal calprotectin in children with gastrointestinal symptoms. J Pediatr Gastroenterol Nutr 2005; 40: 450-455
• 16 Carroll D, Corfield A, Spicer R, Cairns P. Faecal calprotectin concentrations and diagnosis of necrotising enterocolitis. Lancet 2003; 361: 310-311
• 17 Kadalraja R, Patole SK, Muller R, Whitehall JS. Is mesenteric blood flow compromised during phototherapy in preterm neonates?. Arch Dis Child Fetal Neonatal Ed 2004; 89: F564
• 18 Pezzati M, Biagiotti R, Vangi V , et al. Changes in mesenteric blood flow response to feeding: conventional versus fiber-optic phototherapy. Pediatrics 2000; 105: 350-353
• 19 American Academy of Pediatrics Subcommittee on Hyperbilirubinemia. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics 2004; 114: 297-316
• 20 Campeotto F, Baldassarre M, Butel MJ , et al. Fecal calprotectin: cutoff values for identifying intestinal distress in preterm infants. J Pediatr Gastroenterol Nutr 2009; 48: 507-510
• 21 Rougé C, Piloquet H, Butel MJ , et al. Oral supplementation with probiotics in very-low-birth-weight preterm infants: a randomized, double-blind, placebo-controlled trial. Am J Clin Nutr 2009; 89: 1828-1835
• 22 Golden B, Bunn S, Main M. Age-dependent variations in fecal calprotectin concentrations in children. J Pediatr Gastroenterol Nutr 2002; 34: 324-325
• 23 Mohan R, Koebnick C, Schildt J, Mueller M, Radke M, Blaut M. Effects of Bifidobacterium lactis Bb12 supplementation on body weight, fecal pH, acetate, lactate, calprotectin, and IgA in preterm infants. Pediatr Res 2008; 64: 418-422
• 24 Baldassarre ME, Fanelli M, Lasorella ML , et al. Fecal calprotectin (FC) in newborns: is it a predictive marker of gastrointestinal and/or allergic disease?. Immunopharmacol Immunotoxicol 2011; 33: 220-223
• 25 Baldassarre ME, Altomare MA, Fanelli M , et al. Does calprotectin represent a regulatory factor in host defense or a drug target in inflammatory disease?. Endocr Metab Immune Disord Drug Targets 2007; 7: 1-5